TG Therapeutics (TGTX) Competitors

TG Therapeutics (NASDAQ:TGTX) and Beigene (NASDAQ:ONC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Does the media prefer TGTX or ONC?

In the previous week, TG Therapeutics had 2 more articles in the media than Beigene. MarketBeat recorded 10 mentions for TG Therapeutics and 8 mentions for Beigene. TG Therapeutics' average media sentiment score of 1.66 beat Beigene's score of 0.27 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Beigene	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor TGTX or ONC?

TG Therapeutics received 651 more outperform votes than Beigene when rated by MarketBeat users. Likewise, 76.27% of users gave TG Therapeutics an outperform vote while only 72.73% of users gave Beigene an outperform vote.

Company	Underperform	Outperform
TG Therapeutics	Outperform Votes 659 76.27%	Underperform Votes 205 23.73%
Beigene	Outperform Votes 8 72.73%	Underperform Votes 3 27.27%

Do institutionals and insiders hold more shares of TGTX or ONC?

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 48.5% of Beigene shares are held by institutional investors. 10.5% of TG Therapeutics shares are held by insiders. Comparatively, 7.4% of Beigene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has better earnings and valuation, TGTX or ONC?

TG Therapeutics has higher earnings, but lower revenue than Beigene. Beigene is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$329.00M	19.45	$12.67M	$0.14	287.86
Beigene	$3.81B	6.65	-$881.71M	-$6.14	-41.72

Which has more volatility & risk, TGTX or ONC?

TG Therapeutics has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, Beigene has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500.

Do analysts recommend TGTX or ONC?

TG Therapeutics presently has a consensus price target of $40.67, suggesting a potential upside of 0.91%. Beigene has a consensus price target of $318.88, suggesting a potential upside of 24.48%. Given Beigene's stronger consensus rating and higher possible upside, analysts clearly believe Beigene is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Beigene	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is TGTX or ONC more profitable?

TG Therapeutics has a net margin of -5.42% compared to Beigene's net margin of -25.94%. TG Therapeutics' return on equity of -8.32% beat Beigene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	-5.42%	-8.32%	-3.40%
Beigene	-25.94%	-25.12%	-14.95%

Summary

TG Therapeutics beats Beigene on 13 of the 17 factors compared between the two stocks.